3
nature research | reporting summary
April 2018populations. For CD34-PE-Vio770, CD34 mRNA expression has been further observed in the sorted cells by scRNA-seq. CD34,
CD38 and CD10 antibodies used for ddPCR passed the quality control testing for flow cytometric analysis by the manufacturer.Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) TF1 and HEL cell lines were obtained from ATCC; UT7-MPL-CALR WT and Ba/F3-MPL-CALR MUT cells were provided by Elf, et
al (Cancer Discovery, 2016).Authentication Both TF1 and HEL cell lines have been only used as sources of cells with JAK2 WT and JAK2 V617F, respectively, which we
have confirmed previously by sequencing the genomic DNA of those cell lines. UT7-MPL-CALR WT and Ba/F3-MPL-CALR MUT
cells were validated by Elf, et al (Cancer Discovery, 2016) and also confirmed in our GoT data.Mycoplasma contamination The cell lines have been tested negatively for mycoplasma contamination.Commonly misidentified lines
(See ICLAC register)TF1 and HEL cell lines were used for the sole purpose of extracting RNA for JAK2 WT or JAK2 V617F. UT7-MPL-CALR WT and
Ba/F3-MPL-CALR MUT cells were used for the sole purpose of validating GoT procedure for identifying CALR mutant and
wildtype status.Human research participants
Policy information about studies involving human research participants
Population characteristics Study included cryopreserved bone marrow or peripheral blood samples from patients with documented CALR-mutated or JAK2
myeloid neoplasms (6 with essential thrombocythemia, 5 with myelofibrosis, age range: 17-69, gender: 5F, 6M) which had been
banked under specimen acquisition and molecular profiling protocols approved by the Institutional Review Board of Memorial
Sloan-Kettering Cancer Center or Weill Cornell Medicine (Supplementary Table 1). None of the patients had been received
chemotherapy at the time of sample collection. All patients provided informed consent.Recruitment Samples were obtained from patients who sought consultation/were being treated at Memorial Sloan-Kettering Cancer Center
or Weill Cornell Medicine.